267 related articles for article (PubMed ID: 32129697)
1. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
2. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
[TBL] [Abstract][Full Text] [Related]
3. In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.
McCormick A; Swaisland H; Reddy VP; Learoyd M; Scarfe G
Xenobiotica; 2018 Jun; 48(6):555-564. PubMed ID: 28657402
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
5. Assessment of drug-drug interactions of CC-90001, a potent and selective inhibitor of c-Jun N-terminal kinase.
Tong Z; Gaudy A; Tatosian D; Ramirez-Valle F; Liu H; Chen J; Hoffmann M; Surapaneni S
Xenobiotica; 2021 Dec; 51(12):1416-1426. PubMed ID: 35000550
[TBL] [Abstract][Full Text] [Related]
6. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
[TBL] [Abstract][Full Text] [Related]
7. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
[TBL] [Abstract][Full Text] [Related]
8. In vitro assessment of the roles of drug transporters in the disposition and drug-drug interaction potential of olaparib.
McCormick A; Swaisland H
Xenobiotica; 2017 Oct; 47(10):903-915. PubMed ID: 27684210
[TBL] [Abstract][Full Text] [Related]
9. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
10. Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition.
Hanna I; Alexander N; Crouthamel MH; Davis J; Natrillo A; Tran P; Vapurcuyan A; Zhu B
Xenobiotica; 2018 Mar; 48(3):300-313. PubMed ID: 28281384
[TBL] [Abstract][Full Text] [Related]
11. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic Evaluation of the Complex Drug-Drug Interactions of Maraviroc: Contribution of Cytochrome P450 3A, P-Glycoprotein and Organic Anion Transporting Polypeptide 1B1.
Kimoto E; Vourvahis M; Scialis RJ; Eng H; Rodrigues AD; Varma MVS
Drug Metab Dispos; 2019 May; 47(5):493-503. PubMed ID: 30862625
[TBL] [Abstract][Full Text] [Related]
13. Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Liao M; Beltman J; Giordano H; Harding TC; Maloney L; Simmons AD; Xiao JJ
Clin Pharmacokinet; 2022 Nov; 61(11):1477-1493. PubMed ID: 36107395
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Xiao JJ; Nowak D; Ramlau R; Tomaszewska-Kiecana M; Wysocki PJ; Isaacson J; Beltman J; Nash E; Kaczanowski R; Arold G; Watkins S
Clin Transl Sci; 2019 Jan; 12(1):58-65. PubMed ID: 30427584
[TBL] [Abstract][Full Text] [Related]
15. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.
Chen N; Cui D; Wang Q; Wen Z; Finkelman RD; Welty D
Xenobiotica; 2018 Jun; 48(6):637-646. PubMed ID: 28730856
[TBL] [Abstract][Full Text] [Related]
16. Absorption, Metabolism, Distribution, and Excretion of Letermovir.
Menzel K; Kothare P; McCrea JB; Chu X; Kropeit D
Curr Drug Metab; 2021; 22(10):784-794. PubMed ID: 33622223
[TBL] [Abstract][Full Text] [Related]
17. Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib.
Kossatz S; Carney B; Farley C; Weber WA; Drain CM; Reiner T
J Nucl Med; 2018 Aug; 59(8):1316-1320. PubMed ID: 29572258
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
[TBL] [Abstract][Full Text] [Related]
19. The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug-Drug Interactions in a Clinical Setting-Proposal of a Four Component Transporter Cocktail.
Ebner T; Ishiguro N; Taub ME
J Pharm Sci; 2015 Sep; 104(9):3220-8. PubMed ID: 25981193
[TBL] [Abstract][Full Text] [Related]
20. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam.
Reese MJ; Bowers GD; Humphreys JE; Gould EP; Ford SL; Webster LO; Polli JW
Xenobiotica; 2016; 46(5):445-56. PubMed ID: 26340566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
